In This Article:
We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other stocks.
The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results.
Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent.
Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days.
To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume.
An independent distributor in their pharmacy with a range of biopharmaceutical products on display.
ADMA Biologics, Inc. (NASDAQ:ADMA)
ADMA Biologics, Inc. (NASDAQ:ADMA) soared to a new all-time high on Monday after securing the approval of the Food and Drug Administration (FDA) for its innovative yield enhancement production process.
According to the company, the innovative process has demonstrated an ability to increase production yields by approximately 20 percent from the same starting plasma volume.
Following the announcement, ADMA Biologics, Inc. (NASDAQ:ADMA) touched a new record high of $25.67 at intraday trading before early profit-taking pulled its price slightly lower to end the day just up by 12.12 percent at $24.51 apiece.
“This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,” said Adam Grossman, president and CEO of ADMA Biologics, Inc. (NASDAQ:ADMA).
“Looking ahead, we are excited to continue to advance our internal R&D platform—further optimizing production capabilities and progressing novel pipeline programs, most notably SG-001, our pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, which exemplifies our commitment to product and process innovation,” he added.
Overall ADMA ranks 3rd on our list of the best performing stocks on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.